T-DXd in Early-Stage HER2+: What Should Be Your ILD Monitoring Threshold?

In curative-intent settings, the threshold for toxicity is different.

Dr. Hamilton analyzes T-DXd data from DESTINY-Breast05 and DESTINY-Breast11, outlining the required ILD monitoring protocols, explaining when to scan, and detailing why maximum vigilance is critical for early-stage HER2+ patients.